Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Using machine learning, a team of computer scientists and biologists from Western University identified an underlying genomic signature for 29 different COVID-19 virus DNA sequences.

  • GSK Consumer Healthcare is voluntarily recalling five lots (listed below) of Benefiber Healthy Shape Prebiotic Fiber Supplement powder and Benefiber Prebiotic Fiber Supplement powder due to the potential for green plastic pieces or shavings from bottle caps to be present in the product. There is a potential risk of choking or physical injury to the soft tissues of the mouth or gastrointestinal tract of a consumer using the product who may not see a broken piece or shaving of plastic cap.

  • Strides develops and commences export of Favipiravir Antiviral Tablets
    Strides develops and commences export of Favipiravir Antiviral Tablets

    Strides Pharma Science Limited (Strides or Company), a global pharmaceutical company today announced that it has developed and commercialized Favipiravir Antiviral tablets. The product is a generic version of Avigan® of Toyama Chemical, Japan. Favipiravir is an antiviral medication that was initially developed to treat influenza in Japan.

  • Amid the rapidly evolving global coronavirus disease 2019 (COVID-19) pandemic that has already had profound effects on public health and medical infrastructure across the globe, many questions remain about its impact on child health. New research published in the Journal of Clinical Virology indicates that the vulnerability of neonates and children and their role in the spread of the virus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) should be included in preparedness and response plans.

  • Government-enforced social isolation may help relatively affluent populations limit the spread of COVID-19, but these measures can be devasting for the nearly 1 billion people around the globe currently dwelling in urban slums, where physical space is scarce, and many rely on daily wage labor for survival.

  • People with certain heart diseases may be more susceptible to worse outcomes with COVID-19, but the reason why has remained unknown. New research from Mayo Clinic indicates that in patients with one specific type of heart disease obstructive hypertrophic cardiomyopathy (HCM) the heart increases production of the ACE2 RNA transcript and the translated ACE2 protein.

  • Selvita S.A. one of the largest preclinical contract research organizations in Europe, has signed a grant agreement with the National Centre for Research and Development for the development of a cell-based phenotypic platform based on high content imaging system integrated with artificial intelligence data analysis for multiple therapeutic areas, including neuroinflammatory and fibrosis drug discovery (HiScAI – High Content Screening Artificial Intelligence).

Subscribe to Pharma News